Guido Silvestri

This study shows that mRNA vaccines can prime and mature ultrarare HIV bnAb precursor B cells in NHPs, with improved affinity using a modified immunogen.

This study identifies an effector-primed TCF1+ CD8+ T cell state linked to delayed SHIV acquisition and reduced viral load in vaccinated non-human primates.

This study tracks germinal center responses in rhesus macaques over a year, showing prolonged GCs with declining SHM and ongoing plasma cell production.

This study compares acute infection and viral rebound dynamics in ART-treated infant rhesus macaques using a mathematical model to identify increased infected cell death during rebound.

This study shows that IL-6 restricts pre-thymic T cell lineage commitment in SIV-infected rhesus macaques, contributing to loss of viral control.

This study shows that HIV Env trimers coupled to liposomes induce cross-neutralizing antibodies in NHPs that mimic human bNAbs targeting the Env trimer apex.

This study shows that targeting the conserved HIV fusion peptide with modified Env immunogens in rhesus macaques can focus immune responses on neutralizing epitopes.

Membrane-bound BG505 MD39.3 Env trimer delivered as mRNA-LNP reduced base-directed antibody responses in rabbits and macaques and elicited neutralizing antibodies, with memory B cell responses documented in macaques.

The paper investigates how vaccine antigen delivery and adjuvant selection affect the priming of rare HIV broadly neutralizing antibody-precursor B cells in non-human primates, finding that specific dosing and adjuvant combinations enhance their detection in germinal centers.

This study examines how early ART initiation in HIV-infected infants affects antibody development and latent reservoir dynamics, showing their opposing impacts on post-treatment viral rebound.

The paper identifies alterations in redox and iron metabolism associated with HIV-1 latency development and suggests iron metabolism modulators as potential therapeutic tools.